Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Raymond James & Associates

Raymond James & Associates lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 28.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 134,371 shares of the company’s stock after buying an additional 29,997 shares during the period. Raymond James & Associates’ holdings in Intellia Therapeutics were worth $4,097,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in NTLA. Sandia Investment Management LP acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $35,000. Jefferies Financial Group Inc. acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $38,000. ICA Group Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $62,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Intellia Therapeutics by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock worth $72,000 after buying an additional 1,108 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in shares of Intellia Therapeutics during the 1st quarter worth approximately $97,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Transactions at Intellia Therapeutics

In other news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the sale, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at approximately $2,691,027.29. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 3.00% of the company’s stock.

Intellia Therapeutics Trading Up 0.2 %

Intellia Therapeutics stock opened at $25.01 on Friday. The stock has a market cap of $2.40 billion, a P/E ratio of -4.62 and a beta of 1.77. The company has a fifty day simple moving average of $27.71 and a 200-day simple moving average of $28.25. Intellia Therapeutics, Inc. has a 12-month low of $22.67 and a 12-month high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. The business had revenue of ($1.92) million during the quarter, compared to analysts’ expectations of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same period in the previous year, the company earned ($1.40) EPS. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. Wedbush reiterated a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a report on Thursday, February 15th. Canaccord Genuity Group lifted their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Finally, Wolfe Research initiated coverage on shares of Intellia Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $67.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.